Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma

Qi Wu, Ying Tian, Jingqiu Zhang, Hongpeng Zhang, Fengming Gu, Yongdie Lu, Shengnan Zou, Yuji Chen, Pengxiang Sun, Mengyue Xu, Xiaoming Sun, Chao Xia, Hao Chi, A Ying Zhu, Dong Tang _ and Daorong Wang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:102721-102738. https://doi.org/10.18632/oncotarget.21970

Metrics: PDF 2361 views  |   HTML 4462 views  |   ?  


Qi Wu1,*, Ying Tian1,*, Jingqiu Zhang2,*, Hongpeng Zhang1, Fengming Gu1, Yongdie Lu1, Shengnan Zou1, Yuji Chen1, Pengxiang Sun1, Mengyue Xu1, Xiaoming Sun1, Chao Xia3, Hao Chi1, A Ying Zhu1, Dong Tang2 and Daorong Wang2

1Medical College of Yangzhou University, Yangzhou, P.R. China

2Department of General Surgery, Institute of General Surgery, Northern Jiangsu Province Hospital, Clinical Medical College, Yangzhou University, Yangzhou, P.R. China

3Nanjing Medical University, Nanjing, P.R. China

*These authors contributed equally to this work

Correspondence to:

Dong Tang, email: [email protected]

Daorong Wang, email: [email protected]

Keywords: transforming growth factor β(TGF-β), interleukin 6(IL-6), galectin-1, stromal cell-derived factor-1(SDF-1), hepatocyte growth factor (HGF)

Received: July 26, 2017     Accepted: September 21, 2017     Published: October 19, 2017


Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer with poor prognosis because it is highly resistant to traditional chemotherapy and radiotherapy and it has a low rate of surgical resection eligibility. Pancreatic stellate cells (PSC) have become a research hotspot in recent years, and play a vital role in PDAC microenvironment by secreting soluble factors such as transforming growth factor β, interleukin-6, stromal cell-derived factor-1, hepatocyte growth factor and galectin-1. These PSC-derived cytokines and proteins contribute to PSC activation, participating in PDAC cell proliferation, migration, fibrosis, angiogenesis, immunosuppression, epithelial–mesenchymal transition, and chemoradiation resistance, leading to malignant outcome. Consequently, targeting these cytokines and proteins or their downstream signaling pathways is promising for treating PDAC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21970